---
title: "Arrowhead Pharmaceuticals (ARWR) news: convertible notes"
url: "https://aibio.space/companies/arrowhead-pharmaceuticals/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ARWR convertible notes and lawsuit news. Arrowhead Pharmaceuticals news for investors: Arrowhead develops RNA interference medicines that switch off…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Arrowhead's plozasiran moves from rare disease toward a mass market

Arrowhead has a strong late-stage drug, a filing coming before year-end and more than $1.5 billion in cash resources. It also has convertible debt, rising costs and tiny product sales so far. The next test is the FDA filing and what the label says about blood sugar.

Read the full desk view

aibio.space Investor Rank · Opinion

**7** /10 Positive view

Plozasiran is approved in FCS with phase 3 wins in sHTG and a filing due, but product revenue is tiny so far and convertible debt is sizable.

- **Technology**: 2/2

- **Odds**: 2/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 1/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Proven in the liver.** RNAi plozasiran is approved in five markets for FCS and cut triglycerides 79% to 81% in sHTG.

- **Odds**: **Mostly cleared.** The trials are won and the filed-application approval rate is 90.6%, but earlier pipeline assets face phase I to approval odds of 7.9% to 17.0%.

- **Balance sheet**: **Large but leveraged.** Cash resources were $1.57 billion, against $682.7 million of convertible notes and a $215 million voucher purchase.

- **Main risk**: **Commercial scale-up.** Redemplo made about $2.4 million in the June quarter, per MarketBeat's summary of the earnings call, and the sHTG launch will need far more sales spending.

- **Watch next**: sNDA filing before end of 2026, and closing of the voucher purchase.

## Top news on Arrowhead

1. 2026-08-04 Legal [Arrowhead still defending Ionis patent suit over plozasiran after Delaware case was dismissed](https://aibio.space/news/arrowhead-still-defending-ionis-patent-suit-plozasiran-after-delaware/) Ionis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025.
2. 2026-01-07 Debt Financing [Arrowhead Pharmaceuticals prices $625,000,000 of 0.00% convertible notes due 2032](https://aibio.space/news/arrowhead-pharmaceuticals-prices-625-000-000-0-00-percent-convertible/) Arrowhead Pharmaceuticals raised the notes from $500,000,000 to $625,000,000 while selling common stock at the same time. The notes rank behind $254.9 million of secured borrowing.
3. 2025-03-07 Financings [Arrowhead registers resale of 11,926,301 shares by a selling stockholder](https://aibio.space/news/arrowhead-registers-resale-11-926-301-shares-selling-stockholder/) The company will not receive any proceeds from sales by the stockholder. The shares were acquired under a stock purchase agreement dated November 25, 2024.

## Dates

**Before end of 2026**
Planned sNDA to the FDA for plozasiran in severe hypertriglyceridemia, using a priority review voucher [Source](https://www.businesswire.com/news/home/20260830813912/en/)

**Fiscal Q4 2026 (to Sept. 30)**
Expected closing of the $215 million priority review voucher purchase, subject to antitrust clearance [Source](https://www.marketbeat.com/instant-alerts/arrowhead-pharmaceuticals-q3-earnings-call-highlights-2026-08-04/)

**Fourth quarter 2026**
Update on ARO-ALK7 (obesity), per the company's earnings call summary [Source](https://www.marketbeat.com/instant-alerts/arrowhead-pharmaceuticals-q3-earnings-call-highlights-2026-08-04/)

**Mid-2027**
Completion of the phase 3 YOSEMITE study of zodasiran, data in the second half of 2027 [Source](https://www.marketbeat.com/instant-alerts/arrowhead-pharmaceuticals-q3-earnings-call-highlights-2026-08-04/)

## The money

Total cash resources (cash and available-for-sale securities) of $1,566.9 million at June 30, 2026 (fiscal Q3). Arrowhead expects to pay $215 million for a priority review voucher in fiscal Q4. No runway figure was given in the sources reviewed. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm)

Fiscal Q3 2026 (quarter ended June 30) revenue of $75.3 million, mostly from partners (Sarepta, Novartis, Madrigal). MarketBeat's summary of the earnings call put commercial Redemplo revenue at about $2.4 million; the 8-K does not break it out. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm)

## Risks on the record

- Worsening glycemic control was reported in 14.3% of plozasiran patients against 8.7% on placebo in the pooled sHTG trials, and three deaths occurred in the treated group (judged unrelated by the company). [Source](https://www.businesswire.com/news/home/20260830813912/en/)
- Redemplo sales are small (about $2.4 million in the June quarter, per MarketBeat's summary of the earnings call) and revenue depends on partner payments; quarterly net loss attributable to Arrowhead was $194.3 million. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm)
- The balance sheet carries $682.7 million of net convertible notes, $392.5 million tied to sold future royalties and $181.4 million drawn on a credit facility. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Arrowhead Pharmaceuticals?

7 out of 10, our positive view. Plozasiran is approved in FCS with phase 3 wins in sHTG and a filing due, but product revenue is tiny so far and convertible debt is sizable. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What did Arrowhead's SHASTA-3 and SHASTA-4 trials show?

Plozasiran cut median triglycerides by 79% and 81% at 12 months and reduced acute pancreatitis events by 78% in a pooled analysis of 757 patients. Both trials met every prespecified secondary endpoint. [Source](https://www.businesswire.com/news/home/20260830813912/en/)

### When will Arrowhead file plozasiran for severe hypertriglyceridemia?

The company plans to submit a supplemental new drug application to the FDA before the end of 2026. It bought a priority review voucher, which cuts the FDA's review goal from ten months to six. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm)

### How much cash does Arrowhead have?

Total cash resources were $1,566.9 million at June 30, 2026. The company also reports $682.7 million of net convertible notes and expects to pay $215 million for a priority review voucher. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm)

### Is Redemplo approved in Europe?

Yes. The European Commission authorized Redemplo on June 22, 2026 for adults with familial chylomicronemia syndrome, and the label does not require genetic confirmation of the diagnosis. [Source](https://www.businesswire.com/news/home/20260622025442/en)

### How much does Redemplo cost?

Arrowhead set the U.S. list price at $45,000 per patient per year, according to its fiscal second-quarter 2026 report. MarketBeat's summary of the earnings call put commercial Redemplo revenue at about $2.4 million for the quarter ended June 30. [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000045/arwr-202605078kex991.htm)

### What is the latest Arrowhead Pharmaceuticals (ARWR) stock news?

Our latest story on Arrowhead Pharmaceuticals, dated Aug 4, 2026: "Arrowhead still defending Ionis patent suit over plozasiran after Delaware case was dismissed". Ionis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025. [Source](https://aibio.space/news/arrowhead-still-defending-ionis-patent-suit-plozasiran-after-delaware/)

### What is Arrowhead Pharmaceuticals's latest stock offering or financing news?

Our latest financing story, dated Mar 7, 2025: "Arrowhead registers resale of 11,926,301 shares by a selling stockholder". The company will not receive any proceeds from sales by the stockholder. The shares were acquired under a stock purchase agreement dated November 25, 2024. [Source](https://aibio.space/news/arrowhead-registers-resale-11-926-301-shares-selling-stockholder/)

### Who were the underwriters or placement agents on Arrowhead Pharmaceuticals's offering?

From our story: The book-running managers are J.P. Morgan, Jefferies, BofA Securities, Piper Sandler and RBC Capital Markets. [Source](https://aibio.space/news/arrowhead-registers-resale-11-926-301-shares-selling-stockholder/)

### Does Arrowhead Pharmaceuticals have debt, a term loan or convertible notes?

Our latest debt story, dated Jan 7, 2026: "Arrowhead Pharmaceuticals prices $625,000,000 of 0.00% convertible notes due 2032". Arrowhead Pharmaceuticals raised the notes from $500,000,000 to $625,000,000 while selling common stock at the same time. The notes rank behind $254.9 million of secured borrowing. [Source](https://aibio.space/news/arrowhead-pharmaceuticals-prices-625-000-000-0-00-percent-convertible/)

### How long will Arrowhead Pharmaceuticals's cash last?

From our story of Jan 7, 2026: The company says the notes and stock proceeds, with existing cash and investments, should fund planned operations into fiscal year 2029. [Source](https://aibio.space/news/arrowhead-pharmaceuticals-prices-625-000-000-0-00-percent-convertible/)

### Is Arrowhead Pharmaceuticals facing a lawsuit?

Our latest legal story, dated Aug 4, 2026: "Arrowhead still defending Ionis patent suit over plozasiran after Delaware case was dismissed". Ionis sued Arrowhead in California on Sept. 11, 2025 over the '333 patent. Arrowhead, the only named defendant, disputes the claim; its Delaware declaratory action was dismissed Dec. 23, 2025. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/arrowhead-still-defending-ionis-patent-suit-plozasiran-after-delaware/)

### Is Arrowhead Pharmaceuticals a smaller reporting company?

SEC records list Arrowhead Pharmaceuticals, Inc.'s filer category as: Large accelerated filer. Source

### Where is Arrowhead Pharmaceuticals headquartered?

SEC records list its business address as 177 E COLORADO BLVD, PASADENA, CA, 91105. Source

### When does Arrowhead Pharmaceuticals's fiscal year end?

Arrowhead Pharmaceuticals, Inc.'s fiscal year ends on September 30, per SEC records. Source

## Legal and investor matters

Checked against Arrowhead Pharmaceuticals filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Note 7 (Commitments and Contingencies) of the 10-Q filed 2026-08-04 describes one litigation matter, the Ionis patent infringement complaint. It does not mention a securities class action or derivative suit. This covers that filing only. [Source](https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm)

1. 2026-01-12 Financing Arrowhead issues $700 million of 0.00% convertible senior notes due 2032 Arrowhead said in an 8-K that on January 12, 2026 it issued $700,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032 under an underwriting agreement with J.P. Morgan Securities LLC and Jefferies LLC. The $700,000,000 includes $75,000,000 of notes issued on the underwriters' full exercise of their over-allotment option. The filing also covers the related indenture with U.S. Bank Trust Company, National Association as trustee. [Arrowhead 8-K filed 2026-01-12](https://www.sec.gov/Archives/edgar/data/879407/000119312526010582/d19865d8k.htm)
2. 2026-01-07 Financing Arrowhead prices public offering of common stock and pre-funded warrants at $64.50 Arrowhead disclosed in an 8-K that on January 7, 2026 it entered into an underwriting agreement with Jefferies LLC and J.P. Morgan Securities LLC to sell 3,100,776 shares of common stock at a public offering price of $64.50 per share. In lieu of common stock, certain investors were offered pre-funded warrants to purchase up to 1,550,387 shares at $64.499. The warrants are exercisable at the holder's option on payment of the exercise price. [Arrowhead 8-K filed 2026-01-09](https://www.sec.gov/Archives/edgar/data/879407/000119312526007971/d94918d8k.htm)
3. 2025-09-11 Litigation Ionis files patent infringement suit against Arrowhead over plozasiran; Arrowhead had filed a declaratory complaint Arrowhead said in an 8-K that on September 11, 2025 Ionis filed a patent infringement complaint in the Central District of California alleging infringement of the '333 patent. Arrowhead had filed a declaratory judgment complaint in Delaware on September 10, 2025 asking the court to declare the '333 patent invalid and not infringed by its planned commercialization of plozasiran. Arrowhead's 10-Q filed August 4, 2026 says it disputes the allegations and intends to vigorously defend itself. U.S. District Court for the Central District of California; U.S. District Court for the District of Delaware · Status: pending [Arrowhead 8-K filed 2025-09-12](https://www.sec.gov/Archives/edgar/data/879407/000087940725000010/arwr-20250911.htm)
4. 2025-09-02 Other Arrowhead signs license and collaboration with Novartis, $200 million upfront Arrowhead disclosed in an 8-K that on September 2, 2025 it entered into an exclusive license and collaboration agreement with Novartis Pharma AG covering ARO-SNCA, a preclinical RNAi candidate for Parkinson's disease and other synucleinopathies, plus additional targets. Arrowhead will receive $200 million as an upfront payment and is eligible for up to $2 billion in development, regulatory and sales milestones. [Arrowhead 8-K filed 2025-09-02](https://www.sec.gov/Archives/edgar/data/879407/000087940725000004/arwr-20250902.htm)
5. 2024-11-25 Financing Arrowhead signs Sarepta deal: $500 million upfront, $325 million equity Arrowhead's 10-Q filed February 10, 2025 says that on November 25, 2024 it entered into an exclusive license and collaboration agreement with Sarepta. Together with a stock purchase agreement with a Sarepta affiliate, the company expected to receive $500.0 million upfront and $325.0 million in an equity investment, plus $250.0 million in annual installments of $50.0 million over five years. An 8-K reported that Sarepta's chief executive was appointed a director in February 2025 under the investor rights agreement. [Arrowhead 10-Q filed 2025-02-10](https://www.sec.gov/Archives/edgar/data/879407/000162828025004634/arwr-20241231.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Plozasiran (Redemplo) | Familial chylomicronemia syndrome (FCS) | Approved in U.S. (Nov. 2025), EU, China, Australia, Canada [Source](https://www.businesswire.com/news/home/20260622025442/en) |
| Plozasiran | Severe hypertriglyceridemia (sHTG) | Phase 3 SHASTA-3 and SHASTA-4 met endpoints; sNDA planned before end of 2026 [Source](https://www.businesswire.com/news/home/20260830813912/en/) |
| Zodasiran | Homozygous familial hypercholesterolemia | Phase 3 YOSEMITE enrolled; completion expected mid-2027 [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) |
| ARO-INHBE | Obesity (with tirzepatide) and MASH | Phase 1/2a, interim data reported [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) |
| ARO-DIMER-PA | Dual PCSK9 and APOC3 lowering | Phase 1/2a, first subjects dosed [Source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000045/arwr-202605078kex991.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Arrowhead's 100% pancreatitis headline rests on a subgroup of a secondary endpoint

Arrowhead's quarterly release and 10-Q agree on the numbers, and the 10-Q reports sufficient liquidity for twelve months with no going concern language. The gaps are in how the sHTG phase 3 data are framed: the pancreatitis result is a secondary endpoint, the 100% figure comes from a subgroup, and the dedicated pancreatitis trial has not read out. The only legal matter disclosed is a patent complaint from Ionis.

1. Science · weight high Pancreatitis is a secondary endpoint, and the 100% figure is a subgroup **The company said:** "Statistically significant 78% reduction in acute pancreatitis (AP) events versus placebo was observed across the entire sHTG study population, with an unprecedented 100% event reduction in patients with triglycerides above 880 mg/dL and a prior medical history of AP, widely considered to be at the highest risk for AP." [source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) **The record says:** ClinicalTrials.gov lists "Adjudicated AP Event Rate During the Treatment Period Compared to Placebo From Day 1 to Month 12" as a secondary outcome in SHASTA-3 (446 participants) and SHASTA-4 (311), with triglyceride change as the primary outcome. A separate trial, SHASTA-5, lists time to first adjudicated AP event as its primary outcome; it is recruiting 288 participants (estimated) with primary completion estimated for March 2029. The Aug. 30 ESC release reports the pooled all-events result as a 78% reduction (RR 0.22, 95% CI 0.07 to 0.67) with an absolute risk reduction of 4.1%. [source](https://clinicaltrials.gov/study/NCT06347003) **Our view:** A pooled secondary endpoint is useful evidence, and the confidence interval is wide. A subgroup showing zero events says little about the size of the effect, and SHASTA-5 is the study built to test the pancreatitis claim directly.
2. Press release vs filing · weight medium "All prespecified secondary endpoints" is not defined in the release **The company said:** "SHASTA-3 and SHASTA-4 successfully met the primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints in both studies." [source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) **The record says:** ClinicalTrials.gov lists 20 secondary outcomes for SHASTA-3, including new-onset diabetes, worsening of existing diabetes, HbA1c, fasting glucose, MACE rates and anti-drug antibodies, alongside the lipid and pancreatitis measures. The 10-Q repeats the same bullet and does not list which secondary endpoints were tested. [source](https://clinicaltrials.gov/study/NCT06347003) **Our view:** The statement likely refers to the tested secondary hierarchy, but the registry list is much longer. Until the full results are posted, readers cannot tell which measures the sentence covers.
3. Science · weight medium "No new safety signals" sits beside a glycemic imbalance and three deaths **The company said:** "Continued and consistent safety and tolerability profile was demonstrated with no new safety signals and a favorable liver safety profile." [source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) **The record says:** The Aug. 30 ESC release reports worsening glycemic control as an adverse event in 14.3% of plozasiran patients versus 8.7% on placebo in the pooled analysis, and three deaths in the plozasiran group (two cardiovascular, one from chronic myelomonocytic leukemia) that the release says were assessed as unrelated to study treatment. ClinicalTrials.gov lists new-onset diabetes, worsening diabetes and HbA1c as secondary outcomes. [source](https://www.businesswire.com/news/home/20260830813912/en/) **Our view:** The ESC release discloses these figures, so this is about emphasis rather than omission. Glycemic effects matter for a drug aimed at a population with high diabetes rates, and they may figure in the label discussion.
4. Press release vs filing · weight low Redemplo momentum is described in prescriptions, while revenue is mostly partner payments **The company said:** "REDEMPLO prescription volume roughly doubled during the fiscal third quarter." [source](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) **The record says:** The 10-Q says the revenue change "was primarily driven by revenue recognition associated with the Sarepta, Novartis, Madrigal and Sanofi collaboration and license agreements, and partially driven by commercial revenue from REDEMPLO." Collaboration revenue was $72.9 million of $75.3 million total revenue for the quarter. Net loss attributable to Arrowhead was $194.3 million, and the 10-Q says liquidity is expected to be "sufficient" for "at least the next twelve months". [source](https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm) **Our view:** Doubling from a small base is accurate but gives no dollar scale. Neither the release nor the 10-Q states a dollar figure for Redemplo sales. Total revenue of $75.253 million less collaboration revenue of $72.868 million leaves about $2.4 million, which the 10-Q does not label as Redemplo sales.
5. Legal and disclosure record · weight medium Ionis patent complaint over plozasiran; no securities litigation disclosed **The record says:** Note 7 of the 10-Q says: "On September 11, 2025, Ionis filed a Complaint for Patent Infringement against the Company in the United States District Court for the Central District of California alleging patent infringement of the '333 patent by the Company's planned commercialization of investigational plozasiran and seeking damages." The company "disputes the allegations of wrongdoing" and no contingent liabilities were recorded as of June 30, 2026. No securities litigation or enforcement is disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm) **Our view:** The Ionis case targets the same drug at the center of the sHTG filing plan. The 10-Q gives no timetable or damages estimate, so any ruling would be a new fact for investors.

Documents we compared

- [Press release: fiscal 2026 third quarter results (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000058/arwr-202608048kex991.htm) 2026-08-04
- [Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm) 2026-08-04
- [Press release: SHASTA-3 and SHASTA-4 data at ESC 2026 (Business Wire)](https://www.businesswire.com/news/home/20260830813912/en/) 2026-08-30
- [Press release: SHASTA-3 and SHASTA-4 topline results (Business Wire)](https://www.businesswire.com/news/home/20260722499878/en/) 2026-07-22
- [ClinicalTrials.gov NCT06347003 (SHASTA-3)](https://clinicaltrials.gov/study/NCT06347003) 2026-10-08
- [ClinicalTrials.gov NCT06347016 (SHASTA-4)](https://clinicaltrials.gov/study/NCT06347016) 2026-10-09
- [ClinicalTrials.gov NCT06880770 (SHASTA-5)](https://clinicaltrials.gov/study/NCT06880770) 2026-09-21

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ARWR on TradingView](https://www.tradingview.com/symbols/NASDAQ-ARWR/).

## SEC filings and registration

- **SEC name**: Arrowhead Pharmaceuticals, Inc.

- **CIK**: 879407

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ARWR (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: September 30

- **Filer category**: Large accelerated filer

- **Business address**: 177 E COLORADO BLVD, PASADENA, CA, 91105

- **Phone**: 626-696-4702

- **Shares outstanding**: 141,254,467 as of 2026-07-30 (10-Q filed 2026-08-04)

- **Former names**: ARROWHEAD RESEARCH CORP; INTERACTIVE GROUP INC; INTERACTIVE INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/arwr-20260804.htm) filed 2026-08-04
- [10-Q](https://www.sec.gov/Archives/edgar/data/879407/000087940726000057/arwr-20260630.htm) filed 2026-08-04
- [8-K](https://www.sec.gov/Archives/edgar/data/879407/000087940726000050/arwr-20260612.htm) filed 2026-06-16
- [10-Q](https://www.sec.gov/Archives/edgar/data/879407/000087940726000047/arwr-20260331.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/879407/000087940726000045/arwr-20260507.htm) filed 2026-05-07
- [8-K](https://www.sec.gov/Archives/edgar/data/879407/000087940726000037/arwr-20260319.htm) filed 2026-03-20
- [10-Q](https://www.sec.gov/Archives/edgar/data/879407/000087940726000034/arwr-20251231.htm) filed 2026-02-05
- [8-K](https://www.sec.gov/Archives/edgar/data/879407/000087940726000033/arwr-20260205.htm) filed 2026-02-05

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000879407), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/arrowhead-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Arrowhead Pharmaceuticals (ARWR) news: convertible notes", 2026-10-31, https://aibio.space/companies/arrowhead-pharmaceuticals/